These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23400848)

  • 1. Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype.
    Moriyama B; Jarosinski PF; Figg WD; Henning SA; Danner RL; Penzak SR; Wayne AS; Walsh TJ
    Pharmacotherapy; 2013 Mar; 33(3):e19-22. PubMed ID: 23400848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
    Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH
    Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.
    Racil Z; Winterova J; Kouba M; Zak P; Malaskova L; Buresova L; Toskova M; Lengerova M; Kocmanova I; Weinbergerova B; Timilsina S; Rolencova M; Cetkovsky P; Mayer J
    Mycoses; 2012 Nov; 55(6):483-92. PubMed ID: 22429709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.
    Scholz I; Oberwittler H; Riedel KD; Burhenne J; Weiss J; Haefeli WE; Mikus G
    Br J Clin Pharmacol; 2009 Dec; 68(6):906-15. PubMed ID: 20002085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers.
    Wang G; Lei HP; Li Z; Tan ZR; Guo D; Fan L; Chen Y; Hu DL; Wang D; Zhou HH
    Eur J Clin Pharmacol; 2009 Mar; 65(3):281-5. PubMed ID: 18982321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of CYP2C19 phenotype with voriconazole plasma concentration in children.
    Narita A; Muramatsu H; Sakaguchi H; Doisaki S; Tanaka M; Hama A; Shimada A; Takahashi Y; Yoshida N; Matsumoto K; Kato K; Kudo K; Furukawa-Hibi Y; Yamada K; Kojima S
    J Pediatr Hematol Oncol; 2013 Jul; 35(5):e219-23. PubMed ID: 23588332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype.
    Zonios D; Yamazaki H; Murayama N; Natarajan V; Palmore T; Childs R; Skinner J; Bennett JE
    J Infect Dis; 2014 Jun; 209(12):1941-8. PubMed ID: 24403552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients.
    Berge M; Guillemain R; Trégouet DA; Amrein C; Boussaud V; Chevalier P; Lillo-Lelouet A; Le Beller C; Laurent-Puig P; Beaune PH; Billaud EM; Loriot MA
    Eur J Clin Pharmacol; 2011 Mar; 67(3):253-60. PubMed ID: 21038076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical implication of therapeutic drug monitoring on voriconazole from the aspect of the analysis for CYP2C19 gene].
    Kimura M; Yamagishi Y; Kawasumi N; Hagihara M; Hasegawa T; Mikamo H
    Jpn J Antibiot; 2010 Jun; 63(3):255-64. PubMed ID: 20976881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inherited long QT syndrome revealed by antifungals drug-drug interaction.
    Eiden C; Peyrière H; Tichit R; Cociglio M; Amedro P; Blayac JP; Margueritte G; Hillaire-Buys D
    J Clin Pharm Ther; 2007 Jun; 32(3):321-4. PubMed ID: 17489884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
    Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
    Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.
    Driscoll TA; Frangoul H; Nemecek ER; Murphey DK; Yu LC; Blumer J; Krance RA; Baruch A; Liu P
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5780-9. PubMed ID: 21911570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.
    Moriyama B; Falade-Nwulia O; Leung J; Penzak SR; JJingo C; Huang X; Henning SA; Wilson WH; Walsh TJ
    Mycoses; 2011 Nov; 54(6):e877-9. PubMed ID: 21615537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring.
    Hassan A; Burhenne J; Riedel KD; Weiss J; Mikus G; Haefeli WE; Czock D
    Ther Drug Monit; 2011 Feb; 33(1):86-93. PubMed ID: 21192313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers.
    Lei HP; Wang G; Wang LS; Ou-yang DS; Chen H; Li Q; Zhang W; Tan ZR; Fan L; He YJ; Zhou HH
    Ann Pharmacother; 2009 Apr; 43(4):726-31. PubMed ID: 19299322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism.
    Shi HY; Yan J; Zhu WH; Yang GP; Tan ZR; Wu WH; Zhou G; Chen XP; Ouyang DS
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1131-6. PubMed ID: 20669013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics and beyond: variability of voriconazole plasma levels in a patient with primary immunodeficiency.
    Autmizguine J; Krajinovic M; Rousseau J; Théorêt Y; Litalien C; Marquis C; Tapiéro B; Ovetchkine P
    Pharmacogenomics; 2012 Dec; 13(16):1961-5. PubMed ID: 23215888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.
    Kakuda TN; Van Solingen-Ristea R; Aharchi F; Smedt GD; Witek J; Nijs S; Vyncke V; Hoetelmans RM
    J Clin Pharmacol; 2013 Jan; 53(1):41-50. PubMed ID: 23400742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.
    Iwamoto T; Monma F; Fujieda A; Nakatani K; Katayama N; Okuda M
    Clin Ther; 2011 Aug; 33(8):1077-80. PubMed ID: 21802143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.
    Driscoll TA; Yu LC; Frangoul H; Krance RA; Nemecek E; Blumer J; Arrieta A; Graham ML; Bradfield SM; Baruch A; Liu P
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5770-9. PubMed ID: 21968355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.